Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
Physiological Genomics|July 14, 2011
Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammationAngela S Pechenino, Li Lin, Fiona N Mbai, et al.
The American Journal of Cardiology|August 15, 1997
Right ventricular dilation in primary amyloidosis: an independent predictor of survivalA R Patel, S W Dubrey, L A Mendes, et al.
Circulation|May 1, 1985
External noninvasive temporary cardiac pacing: clinical trialsP M Zoll, R H Zoll, R H Falk, et al.
Circulation|October 3, 2001
Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse heartsR Liao, M Jain, P Teller, et al.
The American Journal of Cardiology|February 15, 1987
Sensitivity and specificity of the echocardiographic features of cardiac amyloidosisR H Falk, J F Plehn, T Deering, et al.
Annals of Internal Medicine|May 1, 2001
Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal diseaseL M Dember, V Sanchorawala, D C Seldin, et al.
Transplantation|May 16, 1998
Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathyE A Pomfret, W D Lewis, R L Jenkins, et al.
Bone Marrow Transplantation|November 13, 2001
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisV Sanchorawala, D G Wright, D C Seldin, et al.
Shock (Augusta, Ga.)|December 22, 2005
Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemiaGeorg Baumgarten, Pascal Knuefermann, Gerrit Schuhmacher, et al.
Blood|October 1, 1996
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patientsR L Comenzo, E Vosburgh, R W Simms, et al.
Pageof 15